The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Stadler, Walter M.
Item TypeName
Concept Interferon-alpha
Academic Article Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
Academic Article Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
Academic Article A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Academic Article Renal cancer immunotherapy: a ray of hope or regression to the mean?
Academic Article Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Academic Article Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
Academic Article Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Academic Article Effective therapy for metastatic renal cancer, whither to now.
Academic Article Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
Academic Article Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Academic Article Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
Academic Article Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
Academic Article A phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma (RCC).
Search Criteria
  • Interferon alpha